WE HELP BRING YOUR BIOLOGICALS TO MARKET QUICKLY AND EFFECTIVELY
SYETA Life Sciences has proven expertise in bringing your biologics and biosimilar drugs first to market. Biologics or biological products are drugs that are manufactured from living organisms using complex processes. These drugs must be handled and manufactured with care. Biologics include therapeutic proteins, cell therapies, monoclonal antibodies, and vaccines.
Lack of affordability and accessibility of biologics is driving markets towards biosimilars. Biosimilars are like biologics in terms of purity, safety and potency but there are certain minor differences in the inactive compounds. Recent research has shown that there will be a significant increase in biosimilar sales in the US, with 25 to 35 new biosimilars expected to hit the market. By 2024, the global biosimilars market is expected to exceed more than US$ 15.0 million.
PROVEN EXPERTISE IN BIOSIMILAR AND BIOLOGICS
- Extensive clinical experience and proven trial management
- Ability to design lean protocols for market approval
- Effective cost-efficient management of trials
- Excellent track record for meeting regulatory requirements